Year Founded
2018
Ownership
Private
Employees
~10
Stage
Phase 1
Modalities
Autologous cell therapy

PhotonPharma General Information

FDA cleared to initiate Phase 1 clinical trial for Innocell autologous vaccine in recurrent epithelial ovarian cancer patients. Trial expected to start Q4 2024.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

Innocell
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to PhotonPharma's pipeline data

Book a demo

Key Partnerships

City of Hope

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

PhotonPharma Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view PhotonPharma's complete valuation and funding history, request access »

PhotonPharma Investors

Wellington Partners
Investor Type: Venture Capital
Holding: Minority
The Colorado Office of Economic Development and International Trade
Investor Type: Venture Capital
Holding: Minority
Incubic Venture Capital
Investor Type: Venture Capital
Holding: Minority